| Literature DB >> 32902980 |
Hai-Shan Zhou1,2, Lv-Bin Hu1,2, Han Zhang1,2, Wen-Xin Shan1,2, Yan Wang1,2, Xue Li1,2, Tian Liu1,2, Jing Zhao1,2, Qi-Dong You1,2, Zheng-Yu Jiang1,2.
Abstract
The Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)-ARE (antioxidant response element) pathway is the major defending mechanism against oxidative stresses, and directly disrupting the Keap1-Nrf2 protein-protein interaction (PPI) has been an attractive strategy to target oxidative stress-related diseases, including cardiovascular diseases. Here, we describe the design, synthesis, and structure-activity relationships (SARs) of indoline-based compounds as potent Keap1-Nrf2 PPI inhibitors. Comprehensive SAR analysis and thermodynamics-guided optimization identified 19a as the most potent inhibitor in this series, with an IC50 of 22 nM in a competitive fluorescence polarization assay. Further evaluation indicated the proper drug-like properties of 19a. Compound 19a dose-dependently upregulated genes and protein level of Nrf2 as well as its downstream markers and showed protective effects against lipopolysaccharide-induced injury in both H9c2 cardiac cells and mouse models. Collectively, we reported here a novel indoline-based Keap1-Nrf2 PPI inhibitor as a potential cardioprotective agent.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32902980 DOI: 10.1021/acs.jmedchem.0c01116
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446